Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05QBF
|
|||
| Former ID |
DNC002339
|
|||
| Drug Name |
Devazepide
|
|||
| Synonyms |
DEVAZEPIDE; 103420-77-5; MK-329; Devazepidum; Devazepida; MK 329; L-364,718; UNII-JE6P7QY7NH; L 364718; (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide; JE6P7QY7NH; CHEMBL9506; CHEBI:4460; L-364718; 3(S)-(-)-1,3-Dihydro-3-(2-indolecarbonylamino)-1-methyl-5-phenyl-2H-(1,4)benzodiazepin-2-one; NCGC00159551-01; DSSTox_RID_81331; DSSTox_CID_26092; DSSTox_GSID_46092; 1H-Indole-2-carboxamide,
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gastrointestinal disease [ICD-11: DE2Z] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H20N4O2
|
|||
| Canonical SMILES |
CN1C2=CC=CC=C2C(=NC(C1=O)NC(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=C5
|
|||
| InChI |
1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
|
|||
| InChIKey |
NFHRQQKPEBFUJK-HSZRJFAPSA-N
|
|||
| CAS Number |
CAS 103420-77-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:4460
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholecystokinin receptor type A (CCKAR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Pancreatic secretion | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 878). | |||
| REF 2 | Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.